Clinically, a higher proportion of these tumor-associated (or dysfunctional) NK cells is often linked to poorer patient outcomes and resistance to certain immunotherapies, suggesting that strategies aimed at reversing NK cell dysfunction (e.g., via IL-15 administration or TIGIT blockade) may be promising. Here, IL15 is linked to neoplasm.